<DOC>
	<DOCNO>NCT00003023</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining monoclonal antibody A1G4 BCG may kill tumor cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody A1G4 plus BCG treat patient cancer .</brief_summary>
	<brief_title>Monoclonal Antibody A1G4 Plus BCG Treating Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess toxicity feasibility immunize patient anti-idiotypic rat monoclonal antibody A1G4 combine Bacillus Calmette Guerin ( BCG ) adjuvant . - Determine whether immunization A1G4 combine BCG result immune response direct GD2 ganglioside patient . OUTLINE : All patient treat A1G4 dilute sterile physiologic saline mixed Bacillus Calmette Guerin ( BCG ) organism . The vaccine inject intradermally multiple site . Booster immunization administer week 2 , 4 , 8 , 12 , 20 , 28 , 36 , 44 , 52 . Immunizations administer limb drain lymph node surgically remove previously irradiate . Isoniazid administer 5 day BCG injection . If severe skin reaction present injection site , BCG dose decrease . If skin reaction persist , BCG dose stop A1G4 injection continue . At least 6 patient accrue dose level A1G4 . Dose escalation carry patient follow least 8 week first immunization without encounter grade 3 bad non-skin toxicity . If 0-1 patient experience dose limit toxicity ( DLT ) give dose level , patient accrue next high dose level . If 2 patient experience DLT , MTD define previous dose level . Patients follow least 1 year . PROJECTED ACCRUAL : A total 24 patient expect complete study . If patient remove early study prior evaluation serological response , additional patient accrue 6 patient evaluable serological response .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm GD2 positive tumor include : High risk neuroblastoma ( stage IV , Nmyc amplify , localize neuroblastoma multiply recurrent ) Recurrent metastatic osteosarcoma Recurrent metastatic GD2 positive sarcoma If free disease , patient must fully recover toxic effect complication prior treatment ( chemotherapy surgery ) No great 6 month since last chemotherapy surgery first injection A1G4 PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count great 500/mm^3 Absolute leukocyte count great 500/mm^3 Peripheral Tcell phytohemagglutinin activation ( PHA ) least 50 % normal Hepatic : Not specify Renal : Not specify Cardiovascular : No significant heart disease ( NYHA class III IV ) Other : No serious intercurrent illnesses No active infection require antibiotic No active bleeding No primary immunodeficiency Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent antibiotics No prior mouse antibody detectable human antimouse antibody ( HAMA ) titer Chemotherapy : See Disease Characteristics At least 6 week since nitrosoureas At least 4 week since systemic chemotherapy Endocrine therapy : No concurrent nonsteroidal antiinflammatory agent No concurrent corticosteroid Radiotherapy : At least 4 week since radiotherapy No prior radiation therapy spleen Surgery : See Disease Characteristics No splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>